

References

I-26

1. National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology, prostate cancer. NCCN. Version 1.2016.
2. Shore ND, Mantz CA, Dosoretz DE, et al. Building on Sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. *Cancer Control*. 2013;20(1):1-16.
3. Zustovich F, Fabiani F. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. *Crit Rev Oncol/Hematol*. 2014.
4. Singh B H, Gulley JL. Immunotherapy and therapeutic vaccines in prostate cancer: An update on current strategies and clinical implications. *Asian J Androl*. 2014. 2014;16(3):364-371.
5. Small EJ, Higano CS, Kantoff PW, et al. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with Sipuleucel-T. *Prostate Cancer Prostatic Dis*. 2014;17(3):259-264.
6. Lubaroff DM, Vaena D, Brown JA, et al. Vaccine immunotherapy for prostate cancer: From mice to men. Abstract. *Immunol Res*. 2014;59(1-3):229-235.
7. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. *J Clin Oncol*. 2014;32(30):3436-3448.
8. American Urological Association. Castration-resistant prostate cancer: AUA guideline. 2015. Accessed 11/19/2015.
9. Schelhammer PF, Chodak G, Whitmore JB, et al. Lower baseline PSA predicts greater benefit from sipuleucel-T. *Clinical Advances in Hematology & Oncology*. 2013;(11)6:377-381.
10. Cheng M, Fong L. Beyond Sipuleucel-T: Immune approaches to treating prostate cancer. *Current Treat Options Oncol*. 2014;15(1):115-126.
11. Pieconka C, Telonis D, Mouraviev V, et al. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: Considerations for clinical practice. *Rev Urol*. 2015;17(4):203-210.
12. Scholz M, Yep S, Chancey M, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. *ImmunoTargets*. 2017;11-16.
13. Graff JN, Chamberlain ED. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. *Core Evidence*. 2015;1-10.
14. Yi R, Chen B, Duan P, et al. Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. *Jour Immun Reseach*. 2016:1-10.
15. MICROMEDEX®SOLUTIONS Compendia. 2017. Sipuleucel-T.
16. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Sipuleucel-T.
17. NCCN Drugs & Biologics Compendium™. Sipuleucel-T. 2017. National Comprehensive Cancer Network (NCCN).

18. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.